Additionally, we included Nivolumab, an immune checkpoint inhibitor that targets PD-1, boosting the immune response against cancer cells, via PD-1/PD-L1 axis blockade, and Bevacizumab, a monoclonal antibody that targets and neutralizes vascular endothelial growth factor (VEGF), which has also been reported as having immunostimulatory properties (31, 32). This evidence concerns the gene PDCD1 and cancer.